NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline
2024年7月11日 - 8:00PM
NMD Pharma adds new capabilities with
several senior recruits to support its growing business and
pipeline
Aarhus, Denmark, 11 July 2024 –
NMD Pharma A/S, a clinical-stage biotech company dedicated to
developing novel and improved treatments for patients living with
severe neuromuscular diseases, today announces that it has hired
three senior recruits to its management team to support its growing
business and pipeline. Peter Kasten will begin as Vice President
Finance in August, Cecilia Sparr Eskilsson as Vice President
Project Management in August and Maja B. Nielsen as People &
Culture Director in September.
Mr. Kasten has over 15 years of experience in
financial operations. Most recently, he was at Danske Fragtmænd, a
Danish transport and logistics business, for several years in
different roles of rising seniority. Prior roles include as
Manager, Advisory Services – Finance and Performance Management at
EY (Ernst & Young) and, notably, 10 years in roles of
increasing responsibility at Novo Nordisk, where his work included
projects to establish research centres in the USA and Denmark
relating to its obesity programs.
Dr. Eskilsson is an accomplished scientist with
over 20 years’ expertise in pharmaceutical drug development at
AstraZeneca and LEO Pharma, with extensive experience in leading
global scientific and strategic projects through clinical
development phases. She will build out the company’s project
management organization.
Ms. Nielsen has been leading global Human
Resources departments in various companies since 2007. She joins
from ENABL, the renewable wind energy company, where she is VP of
Global HR. She brings extensive experience in the development of HR
strategies, performance processes and training and development
policies with companies employing personnel across the globe.
Thomas Holm Pedersen, Co-founder and
Chief Executive Officer of NMD Pharma,
said: “Over the last year our business has grown
and matured, and we will have three Phase 2 clinical trials
initiated and recruiting in North America and Europe by the end of
the year. These high-quality additions to our management team,
together with some other key senior hires, bring a wealth of
knowledge and experience to propel our business forward with timely
execution of a growing pipeline and portfolio of projects. I look
forward to working with Peter, Cecilia, and Maja.”
NMD Pharma is developing first-in-class,
muscle-targeted small molecule inhibitor of the skeletal muscle
specific ClC-1 chloride ion channel. Three open Investigational New
Drug (IND) studies are progressing for lead development candidate
NMD670, including a Phase 2 clinical study in spinal muscular
atrophy (SMA) (NCT05794139), a Phase 2b study in generalized
myasthenia gravis (gMG) (NCT06414954) and IND clearance to begin a
Phase 2 study in Charcot-Marie-Tooth disease (CMT)
(NCT06482437).
Patients interested in learning more about any
of these trials are encouraged to read the information on currently
active investigational sites which can be found on each on
clinicaltrials.gov webpage referenced above or to contact a member
of our medical team via email at contact@nmdpharma.com.
-END-
Contacts
NMD Pharma A/SDaniel Brennan,
SVP Corporate and Commercial StrategyE-mail:
contact@nmdpharma.com
ICR ConsiliumMary-Jane Elliott
/ Ashley Tapp / Lindsey Neville E-mail:
NMDPharma@consilium-comms.com Tel: +44 (0)20 3709 5700
About NMD PharmaNMD Pharma A/S
is a clinical-stage biotech company developing a first-in-class
platform of small molecule therapies selectively and directly
targeting the skeletal muscle chloride ion channel (ClC-1) for the
treatment of severe neuromuscular disorders. The Company was
founded on more than 15 years of muscle physiology research with a
focus on regulation of skeletal muscle excitability under physical
activity. NMD Pharma has built a world-leading muscle
electrophysiology platform leveraging the in-depth know-how of
muscle physiology and muscular disorders, small molecule
modulators, enabling technologies and tools as well as in vivo
pharmacology models for discovering and developing proprietary
modulators of neuromuscular function. The Company has built
significant clinical and development expertise as its programmes
have progressed through the clinic. NMD Pharma has raised ~€155
million from investors including Novo Holdings, Lundbeckfonden
BioCapital, INKEF Capital, Roche Venture Fund, and Jeito Capital.
Find out more about us online at http://www.nmdpharma.com.
About NMD670NMD670 is a
first-in-class, muscle-targeted small molecule inhibitor of the
skeletal muscle specific ClC-1 chloride ion channel. It is NMD
Pharma’s lead development program which is being evaluated in 3
Phase 2 clinical studies in neuromuscular diseases. NMD Pharma has
demonstrated that CIC-1 inhibition enhances skeletal muscle
activation and improves skeletal muscle function. This novel
treatment approach has demonstrated compelling preclinical data and
clinical results in myasthenia gravis, spinal muscular atrophy,
Charcot-Marie-Tooth disease and a range of other neuromuscular
disorders. NMD670 has also been granted orphan-drug designation by
the U.S. FDA for treatment of generalised myasthenia gravis (gMG).
In March 2024 a comprehensive data package on NMD670 was published
in the peer-reviewed journal Science Translational Medicine which
generated significant interest including a research highlight
commentary review in Nature Reviews Drug Discovery.